Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foslorapitant and Palonosetron for the Prevention of Nausea and Vomiting Associated With Trastuzumab Rezetecan Therapy
NCT07726433Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of palonosetron in chemotherapy-induced nausea and vomiting (CINV), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jun 2026; status: recruiting.
02
Drugs
palonosetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07726433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726433.